Hepatitis B virus infection and the dialysis patient.
作者： Fabrizio Fabrizi , Piergiorgio Messa , Paul Martin
DOI: 10.1111/J.1525-139X.2008.00437.X
关键词: HBsAg 、 Hepatitis B 、 Dialysis 、 Internal medicine 、 Viral load 、 Kidney disease 、 Medicine 、 Hepatitis B virus 、 Population 、 Immunology 、 Lamivudine
摘要: Prevention of nosocomial transmission hepatitis B virus (HBV) has been a signal achievement in the management chronic kidney disease. The rate serum surface antigen (HBsAg) seropositivity patients on maintenance hemodialysis developed world is currently low (0-10%) but outbreaks acute HBV infection continue to occur this setting. prevalence within dialysis units developing countries appears higher (2-20%) based relatively few reports. Although data are limited, population diminishes survival; viral load HBsAg-positive reportedly and stable over time. Updated recommendations for HBsAg carriers have issued. No rigorously controlled treatment trials with either interferon or lamivudine therapy available.
elsevier.com
sci-hub.se 参考文章(95)
Tadeusz Wojciech Lapinski, Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation World Journal of Gastroenterology. ,vol. 11, pp. 400- 402 ,(2005) , 10.3748/WJG.V11.I3.400
Abeer A. Qadi, Hala Tamim, Ghada Ameen, Abdulrahman Bu-Ali, Sameer Al-Arrayed, Naglaa A. Fawaz, Wassim Y. Almawi, Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: A survey by serologic and molecular methods American Journal of Infection Control. ,vol. 32, pp. 493- 495 ,(2004) , 10.1016/J.AJIC.2003.12.009
Michel Jadoul, , Chantal Cornu, Charles van Ypersele de Strihou, Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian multicenter study Kidney International. ,vol. 53, pp. 1022- 1025 ,(1998) , 10.1111/J.1523-1755.1998.00823.X
Eduardo Gallego, Aurora López, Juan Pérez, Francisco Llamas, Inmaculada Lorenzo, Esperanza López, Maria Luisa Illescas, Elena Andrés, Emilio Olivas, Carmen Gómez-Roldan, None, Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clinical Practice. ,vol. 104, pp. 1- 6 ,(2006) , 10.1159/000093252
Anteo Di Napoli, Patrizio Pezzotti, Domenico Di Lallo, Nicola Petrosillo, Claudia Trivelloni, Salvatore Di Giulio, Lazio Dialysis Registry, Epidemiology of Hepatitis C Virus Among Long-Term Dialysis Patients: A 9-Year Study in an Italian Region American Journal of Kidney Diseases. ,vol. 48, pp. 629- 637 ,(2006) , 10.1053/J.AJKD.2006.07.004
Daniele Marcelli, David Stannard, Ferruccio Conte, Philip J. Held, Francesco Locatelli, Friedrich K. Port, ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States Kidney International. ,vol. 50, pp. 1013- 1018 ,(1996) , 10.1038/KI.1996.403
Salvatore Badalamenti, Anna Catania, Giovanna Lunghi, Giovanni Covini, Elena Bredi, Diego Brancaccio, Maurizio Salvadori, Giovanna Como, Claudio Ponticelli, Giorgio Graziani, Changes in viremia and circulating interferon-α during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? American Journal of Kidney Diseases. ,vol. 42, pp. 143- 150 ,(2003) , 10.1016/S0272-6386(03)00417-7
F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist, G. Dulai, Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Alimentary Pharmacology & Therapeutics. ,vol. 20, pp. 1271- 1277 ,(2004) , 10.1111/J.1365-2036.2004.02290.X
Stanislas Pol, Valérie Thiers, Françoise Carnot, Brigitte Zins, Raffaella Romeo, Pierre Berthelot, Christian Bréchot, Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients Kidney International. ,vol. 47, pp. 1412- 1418 ,(1995) , 10.1038/KI.1995.198
Emlyn Tobillo, Melton Affrime, Thomas C. Marbury, Amy L. Pittenger, Paul Glue, Vijay Batra, Suzanne K. Swan, Marshall Sack, Sheila Jacobs, Samir K. Gupta, Single‐Dose Pharmacokinetics and Safety of Pegylated Interferon‐α2b in Patients with Chronic Renal Dysfunction The Journal of Clinical Pharmacology. ,vol. 42, pp. 1109- 1115 ,(2002) , 10.1177/009127002237996